BGNE - BeiGene, Ltd.
| Previous Close | 187.86 |
| Open | 188.50 |
| Bid | 182.10 x 800 |
| Ask | 195.00 x 900 |
| Day's Range | 185.47 - 189.80 |
| 52 Week Range | 36.51 - 202.88 |
| Volume | 116,925 |
| Avg. Volume | 388,753 |
| Market Cap | 10.183B |
| Beta | 0.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.23 |
| Earnings Date | Aug 7, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 188.46 |
- ACCESSWIRE•6 days ago
Blog Exposure - BeiGene Commenced Phase-3 Trial of Pamiparib in China
LONDON, UK / ACCESSWIRE / May 21, 2018 / If you want access to our free research report on BeiGene, Ltd (NASDAQ: BGNE), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BGNE as the Company's latest news hit the wire. On May 17, 2018, the Company announced that the first patient was enrolled in a Phase-3 clinical trial in China assessing pamiparib (BGB-290), an investigational PARP inhibitor, in patients with platinum-sensitive recurrent ovarian cancer. Active-Investors.com is currently working on the research report for Epizyme, Inc. (NASDAQ: EPZM), which also belongs to the Healthcare sector as the Company BeiGene.
Motley Fool•8 days agoThese Stocks Have Quadrupled in Just 1 Year
Find out how these companies have defied a choppy market.
- GlobeNewswire•10 days ago
BeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Chinese Patients with Ovarian Cancer
BeiGene, Ltd. (BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the first patient was enrolled in a Phase 3 clinical trial in China of pamiparib (BGB-290), an investigational PARP inhibitor, in patients with platinum-sensitive recurrent ovarian cancer. “We are pleased to announce the initiation of this Phase 3 trial of pamiparib in China as a potential maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer.
- GlobeNewswire•12 days ago
BeiGene to Present at the 2018 UBS Global Healthcare Conference
CAMBRIDGE, Mass. and BEIJING, China, May 15, 2018-- BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology ...
- GlobeNewswire•18 days ago
BeiGene Reports First Quarter 2018 Financial Results
CAMBRIDGE, Mass. and BEIJING, China, May 09, 2018-- BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology ...
- ACCESSWIRE•20 days ago
Could Unknown Orgenesis (ORGS) Be The Next Double Or Triple In The Cell Therapy Space?
Many investors missed the trend when Chinese pharmaceutical companies got hot. Many of these stocks are up 3-fold or more in the last year as Chinese biotechnology companies have played catch-up to U.S. companies in the booming cell therapy market. As a result, developers are turning to specialized contract development manufacturing organizations (CDMOs).
- GlobeNewswire•23 days ago
BeiGene to Present at the Deutsche Bank 43rd Annual Health Care Conference
CAMBRIDGE, Mass., and BEIJING, China, May 04, 2018-- BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology ...
- GlobeNewswire•26 days ago
BeiGene Appoints Senior Pharmaceutical Executive Dr. Xiaobin Wu as General Manager of China and President of BeiGene, Ltd.
BeiGene, Ltd. (BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced the appointment of Dr. Xiaobin Wu to the position of General Manager of China and President of BeiGene, Ltd., reporting to John Oyler, Founder, CEO and Chairman. Dr. Wu has more than 25 years of experience in the pharmaceutical industry including 17 years leading China operations of multinational companies, with expertise in integrated research and development, strategy, commercialization, and general management.
- GlobeNewswire•last month
BeiGene Presents Clinical Data on Pamiparib in Chinese Patients with Ovarian Cancers or Triple-Negative Breast Cancer at the American Association for Cancer Research Annual Meeting
BEIJING, China and CAMBRIDGE, Mass., April 16, 2018-- BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology ...
- GlobeNewswire•last month
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Relapsed or Refractory Mature T-and NK-Cell Lymphomas
CAMBRIDGE, Mass. and BEIJING, China, April 16, 2018-- BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology ...
- Motley Fool•last month
These 3 Biotech Stocks Are Up More Than 500% Over the Last 3 Years
Find out how these three put up huge gains while their peers struggled.
- ACCESSWIRE•last month
Wired News – BeiGene Enrolled First Patient in Global Phase-2 Trial of Tislelizumab with Previously Treated HCC Patients
Stock Monitor: Madrigal Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 12, 2018 / Active-Investors.com has just released a free research report on BeiGene, Ltd (NASDAQ: BGNE ). If you want ...
- GlobeNewswire•2 months ago
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Previously Treated Hepatocellular Carcinoma
CAMBRIDGE, Mass. and BEIJING, China, April 10, 2018-- BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology ...
Market Realist•2 months agoWhat Drove BeiGene Stock in March 2018?
BeiGene (BGNE) stock has risen 16.9%, from $143.73 on March 1, 2018, to $168 on March 29, 2018. Originally founded as a research and development company, BeiGene has evolved into a biopharmaceutical company focused on developing oncology therapies such as BTK inhibitor zanubrutinib, PD-1 antibody tislelizumab, and PARP inhibitor pamiparib.
- GlobeNewswire•2 months ago
Research Report Identifies Teck Resources, Adverum Biotechnologies, BeiGene, IPG Photonics, Arsanis, and G1 THERAPEUTICS with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, April 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•2 months ago
BeiGene Appoints J. Samuel Su to its Board of Directors
BEIJING, China and CAMBRIDGE, Mass., April 03, 2018-- BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology ...
- ACCESSWIRE•2 months ago
Today’s Research Reports on Trending Tickers: BeiGene and Exact Sciences
NEW YORK, NY / ACCESSWIRE / March 20, 2018 / The S&P 500 and the Nasdaq posted their worst daily loss since February 8th on Monday as a sharp decline in Facebook shares triggered a selloff in the technology ...
- Motley Fool•2 months ago
2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?
These two highfliers have risen roughly fourfold over the past year. Here's how they could keep it going.
- GlobeNewswire•2 months ago
Report: Exploring Fundamental Drivers Behind BeiGene, Snyder's-Lance, China Lodging Group, Amdocs, LG Display Co., and Acacia Communications — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, March 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Motley Fool•3 months ago
The Revolutionary New HIV Drug You've Probably Never Heard Of
The FDA recently approved a groundbreaking new HIV treatment, and it isn't from Gilead or Glaxo.
- GlobeNewswire•3 months ago
BeiGene to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. and BEIJING, China, March 05, 2018-- BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology ...
- Reuters•3 months ago
China's Tasly to list biotech arm in $1 bln Hong Kong IPO - sources
China's Tasly Pharmaceutical Group is planning to list its biopharma unit in Hong Kong to raise about $1 billion, in what is likely to be the largest biotech float in the city this year, people with knowledge of the matter said. The plan comes as Hong Kong Exchanges and Clearing , the city's exchange operator, is proposing changes to its listing rules to woo early-stage drug developers. Tianjin-based Tasly, well known for producing traditional Chinese medicines, aims to list its wholly owned biopharma arm - Shanghai Tasly Pharmaceutical in the second half of 2018, said the people.
- GuruFocus.com•3 months ago
Beigene Ltd (BGNE) CEO John Oyler Sold $14.4 million of Shares
CEO of Beigene Ltd (NASDAQ:BGNE) John Oyler sold 99,000 shares of BGNE on 03/02/2018 at an average price of $145.63 a share.
- GlobeNewswire•3 months ago
BeiGene Reports Fourth Quarter and Full Year 2017 Financial Results
CAMBRIDGE, Mass. and BEIJING, China, Feb. 28, 2018-- BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology ...
- GlobeNewswire•3 months ago
BeiGene Announces Approval of REVLIMID® for Newly Diagnosed Multiple Myeloma in China
BEIJING, China, and CAMBRIDGE, Mass., Feb. 27, 2018-- BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology ...
